Cardlytics Inc (CDLX) FinancialsCDLXCardlytics Inc

Cardlytics Inc (CDLX) generates its revenue primarily from Cardlytics Direct, which accounts for 100.0% of total sales, equivalent to $34.32M. Understanding this concentration is critical for investors evaluating how CDLX navigates market cycles within the Software industry.

Evaluating the bottom line, Cardlytics Inc maintains a gross margin of 46.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -12.78%, while the net margin is -23.48%. These profitability ratios, combined with a Return on Equity (ROE) of -513.16%, provide a clear picture of how effectively CDLX converts its operational activities into shareholder value.

In the context of the broader market, CDLX competes directly with industry leaders such as OPAD and QH. With a market capitalization of $11.49M, it holds a leading position in the sector. When comparing efficiency, CDLX's gross margin of 46.65% stands against OPAD's 8.32% and QH's 0.60%. Such benchmarking helps identify whether Cardlytics Inc is trading at a premium or discount relative to its financial performance.

Cardlytics has reported a gross margin of 46.65% in Q2 2026, showing some operational efficiency, but the net income remains negative, with a Q2 loss of $14.88 million. The company's total revenue for Q2 was $36.88 million, which is a decline from previous quarters, indicating ongoing challenges in revenue generation.